Published in Pharma Business Week, July 30th, 2012
Under the terms of the transaction, Human Genome shareholders will receive only $14.25 in cash for each of Human Genome stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Human Genome for not acting in the Company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.